Pasar al contenido principal

IDENTIFICACION DE LOS MECANISMOS INMUNOLOGICOS QUE CONTROLAN LA PROGRESION A MIELOMA EN LOS PACIENTES CON MIELOMA QUIESCENTE "NON-EVOLVING" Y "EVOLVING" PARA EL DISEÑO DE NUEVAS ESTRATEGIAS TERAPEUTICAS

PI20/00436

•
Nombre agencia financiadora Instituto de Salud Carlos III
Acrónimo agencia financiadora ISCIII
Programa Programa Estatal de Generación de Conocimiento y Fortalecimiento del Sistema Español de I+D+I
Subprograma Subprograma Estatal de Generación de Conocimiento
Convocatoria Proyectos de Investigación en Salud
Año convocatoria 2020
Plan Estatal 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario FUNDACION PRIVADA CLINIC
Centro realización HOSPITAL CLINICO Y PROVINCIAL DE BARCELONA

Resultados relacionados

Resultados totales (Incluyendo duplicados): 1
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Gene Expression Analysis of the Bone Marrow Microenvironment Reveals Distinct Immunotypes in Smoldering Multiple Myeloma Associated to Progression to Symptomatic Disease

  • Isola, Ignacio
  • Brasó-Maristany, Fara|||0000-0001-5440-9643
  • Moreno, David F.
  • Mena, Mari Pau
  • Oliver-Caldés, Aina|||0000-0002-7921-5420
  • Paré Brunet, Laia
  • Rodríguez Lobato, Luis Gerardo|||0000-0001-5694-0921
  • Martín-Antonio, B|||0000-0003-0612-2693
  • Cibeira, María Teresa|||0000-0002-4036-754X
  • Bladé Creixenti, Juan|||0000-0002-4563-3405
  • Rosiñol, Laura|||0000-0002-2534-9239
  • Prat, Aleix|||0000-0003-2377-540X
  • Lozano, Ester|||0000-0002-6307-9807
  • Fernández de Larrea, Carlos|||0000-0003-4930-9255
Background: We previously reported algorithms based on clinical parameters and plasma cell characteristics to identify patients with smoldering multiple myeloma (SMM) with higher risk of progressing who could benefit from early treatment. In this work, we analyzed differences in the immune bone marrow (BM) microenvironment in SMM to better understand the role of immune surveillance in disease progression and to identify immune biomarkers associated to higher risk of progression. Methods: Gene expression analysis of BM cells from 28 patients with SMM, 22 patients with monoclonal gammopathy of undetermined significance (MGUS) and 22 patients with symptomatic MM was performed by using Nanostring Technology. Results: BM cells in SMM compared to both MGUS and symptomatic MM showed upregulation of genes encoding for key molecules in cytotoxicity. However, some of these cytotoxic molecules positively correlated with inhibitory immune checkpoints, which may impair the effector function of BM cytotoxic cells. Analysis of 28 patients with SMM revealed 4 distinct clusters based on immune composition and activation markers. Patients in cluster 2 showed a significant increase in expression of cytotoxic molecules but also inhibitory immune checkpoints compared to cluster 3, suggesting the presence of cytotoxic cells with an exhausted phenotype. Accordingly, patients in cluster 3 had a significantly longer progression free survival. Finally, individual gene expression analysis showed that higher expression of TNF superfamily members (TNF, TNFAIP3, TNFRSF14) was associated with shorter progression free survival. Conclusions: Our results suggest that exhausted cytotoxic cells are associated to high-risk patients with SMM. Biomarkers overexpressed in patients with this immune gene profile in combination with clinical parameters and PC characterization may be useful to identify SMM patients with higher risk of progression.